Menu
US
Shop
Request a Quote
Contact Us
US
CAR-T-Research-LitReview1920
Application Note

A comparative study of two immunoassay platforms to determine lentivirus titer for CAR-T development

The main vectors of gene therapy in research are viruses. The most popular tool for gene delivery is a genetically modified lentivirus. Modified lentivirus (HIV-1) vectors retain their ability to infect undivided cells, thereby increasing their ability to transduce a wide variety of cells, including those that are difficult to transduce. This advantage enables the stable long-term expression of a transgene.

In immunotherapy, CAR-T cells are manufactured by transducing the CAR gene with an HIV-1 vector in T cells to express a specific chimeric p24 protein on their surface. This allows them to recognize cancer cells and destroy them. These CAR-T cells must be generated individually to treat each patient.

This application note demonstrates a comparative quantification of the p24 titer in a lentiviral GFP control sample using Alliance HIV-1 p24 Antigen ELISA and p24 AlphaLISA immunoassay platforms.

Check out the different sections of this application note:

  • A lentiviral vector that encodes the CAR construct
  • Determination of the efficiency of transient co-transfection by measuring viral titer
  • Detection of the presence of a p24 HIV-1 specific antibody in the sample
  • Quantification of targets present in the sample

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

A comparative study of two immunoassay platforms to determine lentivirus titer for CAR-T development

Download Application Note